These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the ...

Single-molecule biophysics is the study of the dynamics and interactions of individual biomolecules to understand how they carry out their functions in living cells. For example, monitoring the ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

Neurocrine Biosciences, Inc. ( NASDAQ: NBIX) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive Officer Matt ...

Neurocrine Biosciences, Inc. has a 1 year low of $110.95 and a 1 year high of $157.98. The stock’s 50 day moving average price is $137.92 and its 200 day moving average price is $131.51.

SAN DIEGO—Gano Kyle, the Chief Executive Officer of Neurocrine Biosciences Inc. (NASDAQ:NBIX), a $15.4 billion biopharmaceutical company currently rated as having GREAT financial health ...

Eric Benevich, the Chief Commercial Officer of Neurocrine Biosciences Inc (NASDAQ:NBIX), recently sold 1,207 shares of the company's common stock. The shares were sold at an average price of $152. ...

In the last three months, 7 analysts have published ratings on Neurocrine Biosciences NBIX, offering a diverse range of perspectives from bullish to bearish. The table below offers a condensed ...

Neurocrine Biosciences stock opened at $150.10 on Tuesday. The stock has a market cap of $15.20 billion, a price-to-earnings ratio of 40.24 and a beta of 0.33. The company’s 50-day moving ...

We recently compiled a list of the 12 Best Low Risk High Growth Stocks to Invest In. In this article, we are going to take a look at where Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stands against the ...